San Rocco Therapeutics v. Memorial Sloan-Kettering: Dismissed Without Prejudice After 757 Days
San Rocco Therapeutics filed a patent infringement action against Memorial Sloan-Kettering Cancer Center in the SDNY, asserting two patents covering vectors encoding human globin genes for treating hemoglobinopathies. After 757 days of litigation, the parties filed a stipulation of voluntary dismissal without prejudice under Rule 41(a)(1)(A)(ii).
Gene Therapy Infringement Action Ends Without Merits Ruling in SDNY
On October 5, 2021, San Rocco Therapeutics, LLC filed a patent infringement action against Memorial Sloan-Kettering Cancer Center and Sloan Kettering Institute of Cancer Research in the Southern District of New York (Case No. 1:21-cv-08206). The suit asserted US7541179B2 and US8058061B2, both covering vectors encoding the human globin gene and their use in treating hemoglobinopathies — a category of blood disorders including sickle cell disease and beta-thalassemia. Judge Vernon S. Broderick presided.
The recorded basis of termination is 'Dismissed without Prejudice.' The docket order is a Stipulation of Voluntary Dismissal filed by San Rocco Therapeutics, LLC, stating the action is voluntarily dismissed without prejudice against both defendants pursuant to Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure. No merits determination was reached. The specific terms underlying the parties' decision to stipulate to dismissal are not disclosed in the available record.
The case ran for 757 days before dismissal, suggesting substantive litigation activity occurred before the parties agreed to end proceedings. A dismissal without prejudice preserves San Rocco's ability to refile claims in the future, meaning the underlying patent dispute over hemoglobinopathy gene therapy technology is not necessarily resolved. What drove the parties to this resolution — and whether any out-of-court arrangement exists — is not disclosed in the public record.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 757 days
757 days from filing to dismissal — longer than the median SDNY patent case
US7541179B2 & US8058061B2 — Human Globin Gene Vectors for Hemoglobinopathy Treatment
Any R&D team or company developing lentiviral or other vector-based gene therapies targeting hemoglobinopathies — including sickle cell disease and beta-thalassemia — should assess their freedom to operate against US7541179B2 and US8058061B2. The litigation against Memorial Sloan-Kettering demonstrates that San Rocco is prepared to assert these patents against major research institutions. The without-prejudice dismissal means the patents remain live and their claim scope has not been judicially narrowed.
Official order — verbatim text
The stipulation records a mutual agreement to dismiss without prejudice under Rule 41(a)(1)(A)(ii), filed by San Rocco Therapeutics. This procedural mechanism closes the docket without any judicial finding on infringement or patent validity. For both parties, the legal effect is that the claims asserted — and the defences raised — remain untested and unresolved as a matter of judicial record. The specific terms and circumstances that led the parties to this stipulation are not disclosed in the available record.
Dismissed without prejudice: what the stipulated dismissal means for both parties
Rule 41(a)(1)(A)(ii) voluntary dismissal without prejudice
A stipulated dismissal under Rule 41(a)(1)(A)(ii) requires the consent of all parties who have appeared. Dismissal without prejudice means the court did not adjudicate the merits — no finding of infringement, validity, or invalidity was entered. San Rocco retains the legal right to refile these claims, subject to applicable statutes of limitations and any tolling considerations.
No merits adjudicationSan Rocco preserves its right to refile — but gains no judicial validation
A dismissal without prejudice is neither a win nor a loss for the patent holder. San Rocco's patents US7541179B2 and US8058061B2 remain in force and unadjudicated on validity or infringement. The door to future enforcement is left open. However, the absence of a merits ruling means no precedent favourable to the plaintiff was established in this proceeding.
Patents remain enforceableSloan-Kettering faces no judgment — but the threat is not permanently extinguished
Memorial Sloan-Kettering Cancer Center and Sloan Kettering Institute of Cancer Research exit this litigation without any adverse finding. No injunction, damages, or liability was imposed. That said, because the dismissal is without prejudice, the defendants cannot treat this as a permanent resolution of the patent claims unless a statute of limitations or other bar applies. Continued monitoring of San Rocco's patent portfolio is advisable.
No liability imposedUnresolved gene therapy patent scope creates ongoing uncertainty
The two asserted patents covering vectors for human globin gene delivery remain unadjudicated. For companies active in hemoglobinopathy gene therapy — including those developing lentiviral or other vector-based treatments — the lack of a validity or claim-scope ruling means the competitive and freedom-to-operate risk posed by these patents is unchanged. Developers in this space should treat these patents as live enforcement risks.
FTO risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | San Rocco Therapeutics, LLC | Company | /Search in Eureka ↗ |
| Defendant | Memorial Sloan-Kettering Cancer Center | Individual | /Search in Eureka ↗ |
| Co-Defendant | Sloan Kettering Institute Of Cancer Research | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexandra Cavazos | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Crystal Law | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | David A. Forrest | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Erika Levin | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Lenore Faye Horton | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Mary Jean Kim | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Natalie I. Uhlemann | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Wanda Deloris French-Brown | Attorney | Counsel for San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Fox Rothschild LLP | Law Firm | Representing San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Horton Legal Strategies PLLC | Law Firm | Representing San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Loeb & Loeb LLP | Law Firm | Representing San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Plaintiff law firm | White & Case LLP | Law Firm | Representing San Rocco Therapeutics, LLCSearch in Eureka ↗ |
| Defendant counsel | Christopher Ronald Noyes | Attorney | Counsel for Memorial Sloan-Kettering Cancer CenterSearch in Eureka ↗ |
| Defendant counsel | Robert J. Gunther | Attorney | Counsel for Memorial Sloan-Kettering Cancer CenterSearch in Eureka ↗ |
| Defendant law firm | Wilmer Cutler Pickering Hale & Dorr LLP | Law Firm | Representing Memorial Sloan-Kettering Cancer CenterSearch in Eureka ↗ |
| Presiding judge | Judge Vernon S. Broderick | Judge | New York Southern District CourtSearch in Eureka ↗ |
R&D signals in the gene therapy vector IP space
Forward-looking patent intelligence on globin gene delivery vectors, San Rocco's portfolio activity, and competitive filing trends across the hemoglobinopathy gene therapy sector.
San Rocco Therapeutics' broader patent estate in gene delivery
San Rocco's assertion of two patents covering human globin gene vectors suggests a focused IP position in hemoglobinopathy gene therapy. Understanding the full scope of their portfolio — including related applications, continuations, or divisionals — is critical for competitors and potential licensees active in the same vector technology space.
Portfolio monitoringFiling trends in lentiviral vectors for globin gene therapy
The past decade has seen accelerating patent filings around lentiviral and AAV vector constructs for correcting haemoglobin disorders. Mapping filing trends across academic institutions, biotech companies, and established pharma in this space reveals where innovation is concentrating — and where white-space opportunities or crowded claim territories exist.
Lentiviral vector filingsMemorial Sloan-Kettering's gene therapy patent activity
As a major academic research institution, Memorial Sloan-Kettering Cancer Center and its affiliated Sloan Kettering Institute file patents across oncology and gene therapy. Tracking their filings in vector-based gene delivery and hemoglobinopathy research reveals the breadth of their independent IP position and any potential overlap with third-party patent estates.
Academic IP activityAdjacent innovation opportunities in haemoglobin disorder gene therapy
Beyond the specific vector constructs at issue in this case, adjacent R&D areas — including ex-vivo gene editing approaches, next-generation vector capsids, and non-viral delivery modalities for globin gene correction — may represent lower-encumbrance development paths. Analysing claim coverage gaps in the existing patent landscape can surface actionable white space.
White-space mappingSimilar gene therapy patent infringement cases in the SDNY and federal courts
Explore patent infringement cases involving gene therapy vectors and hemoglobinopathy treatment technology litigated in the Southern District of New York and related federal courts.
What this case signals for the gene therapy IP landscape
A 757-day infringement action ending without a merits ruling leaves the hemoglobinopathy gene therapy patent landscape unresolved.
Unadjudicated patents remain a live enforcement risk for hemoglobinopathy developers
US7541179B2 and US8058061B2 were never tested on validity or infringement. Any company developing vector-based therapies for sickle cell disease, beta-thalassemia, or related conditions should treat these patents as active risks requiring FTO analysis before advancing products.
Without-prejudice dismissal signals the dispute is unresolved, not concluded
The absence of a consent judgment or with-prejudice dismissal means San Rocco retains optionality. Companies in this sector — particularly those whose pipelines touch globin gene delivery vectors — should monitor San Rocco's litigation activity and patent portfolio for signs of renewed enforcement.
San v Memorial — key questions answered
San Rocco Therapeutics asserted two patents: US7541179B2 (application no. US10/188221) and US8058061B2 (application no. US12/433412). Both cover vectors encoding the human globin gene and their use in treating hemoglobinopathies such as sickle cell disease and beta-thalassemia.
The case was dismissed without prejudice. The parties filed a Stipulation of Voluntary Dismissal under Rule 41(a)(1)(A)(ii) of the Federal Rules of Civil Procedure. No merits ruling on infringement or patent validity was issued. The recorded basis of termination is 'Dismissed without Prejudice.'
A dismissal without prejudice generally preserves the plaintiff's right to refile the same claims, subject to applicable statutes of limitations and any other procedural bars. No finding on the merits was entered, so the underlying patent claims remain unadjudicated. Whether San Rocco will refile is not disclosed in the public record.
US7541179B2 covers vectors encoding the human globin gene for use in treating hemoglobinopathies. The patent was never adjudicated on validity or infringement in this case, meaning its claim scope remains an open FTO question for developers of lentiviral or other vector-based gene therapies targeting sickle cell disease, beta-thalassemia, and related conditions.
San Rocco Therapeutics was represented by Fox Rothschild LLP, Horton Legal Strategies PLLC, Loeb & Loeb LLP, and White & Case LLP. Memorial Sloan-Kettering Cancer Center and Sloan Kettering Institute of Cancer Research were represented by Wilmer Cutler Pickering Hale & Dorr LLP.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.